| pubmed-article:18519699 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18519699 | lifeskim:mentions | umls-concept:C0033578 | lld:lifeskim |
| pubmed-article:18519699 | lifeskim:mentions | umls-concept:C0597712 | lld:lifeskim |
| pubmed-article:18519699 | lifeskim:mentions | umls-concept:C0013203 | lld:lifeskim |
| pubmed-article:18519699 | lifeskim:mentions | umls-concept:C0598934 | lld:lifeskim |
| pubmed-article:18519699 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:18519699 | lifeskim:mentions | umls-concept:C2604082 | lld:lifeskim |
| pubmed-article:18519699 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:18519699 | pubmed:dateCreated | 2008-6-3 | lld:pubmed |
| pubmed-article:18519699 | pubmed:abstractText | Patients with hormone-refractory prostate cancer (HRPC) have an estimated median survival of only 10 months because of acquired drug resistance, urging the need to develop therapies against the drug-resistant HRPC phenotype. Accumulating evidence suggests that overexpressing antiapoptotic Bcl-2 family proteins is at least partially responsible for the development of drug resistance among HRPC patients. Antagonizing the antiapoptotic Bcl-2 family proteins, therefore, is one potential approach to circumventing drug resistance in HRPC. WL-276 was developed as a small-molecule antagonist against antiapoptotic Bcl-2 family proteins, with binding potency comparable to (-)-gossypol. Overexpressing Bcl-2 or Bcl-X(L) failed to confer resistance to WL-276. WL-276 also effectively induced apoptosis in PC-3 cells. In addition, three PC-3 cell lines with acquired drug resistance against standard cancer chemotherapies were more sensitive to WL-276 than the parent PC-3 cell line. The increased cytotoxicity toward drug-resistant PC-3 cells shows the clinical potential of WL-276 against HRPC that is resistant to conventional therapies. The anticancer activity of WL-276 was manifested in its suppression of PC-3-induced prostate tumor growth in vivo. The selective toxicity of WL-276 against drug-resistant PC-3 cells and its in vivo suppression of PC-3 prostate tumor growth suggest that WL-276 is a promising lead candidate for the development of Bcl-2 antagonists against drug-resistant HRPC. | lld:pubmed |
| pubmed-article:18519699 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18519699 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18519699 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18519699 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18519699 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:18519699 | pubmed:issn | 1538-7445 | lld:pubmed |
| pubmed-article:18519699 | pubmed:author | pubmed-author:SlatonJoel... | lld:pubmed |
| pubmed-article:18519699 | pubmed:author | pubmed-author:XingChengguoC | lld:pubmed |
| pubmed-article:18519699 | pubmed:author | pubmed-author:SloperDaniel... | lld:pubmed |
| pubmed-article:18519699 | pubmed:author | pubmed-author:TianDefengD | lld:pubmed |
| pubmed-article:18519699 | pubmed:author | pubmed-author:WangLiangyouL | lld:pubmed |
| pubmed-article:18519699 | pubmed:author | pubmed-author:AddoSadiya... | lld:pubmed |
| pubmed-article:18519699 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18519699 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18519699 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:18519699 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18519699 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18519699 | pubmed:pagination | 4377-83 | lld:pubmed |
| pubmed-article:18519699 | pubmed:dateRevised | 2011-5-10 | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:meshHeading | pubmed-meshheading:18519699... | lld:pubmed |
| pubmed-article:18519699 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18519699 | pubmed:articleTitle | WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. | lld:pubmed |
| pubmed-article:18519699 | pubmed:affiliation | Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA. | lld:pubmed |
| pubmed-article:18519699 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18519699 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18519699 | lld:pubmed |
